Hoth Therapeutics, Inc. - FORM 10-Q - EX-32.1 - CERTIFICATION - August 13, 2020

Attached files

file filename
EX-10.9 - PATENT LICENSE AGREEMENT BY AND BETWEEN THE COMPANY AND THE GEORGE WASHINGTON UN - Hoth Therapeutics, Inc.f10q0620ex10-9_hoththerap.htm
EX-32.2 - CERTIFICATION - Hoth Therapeutics, Inc.f10q0620ex32-2_hoththerap.htm
EX-31.2 - CERTIFICATION - Hoth Therapeutics, Inc.f10q0620ex31-2_hoththerap.htm
EX-31.1 - CERTIFICATION - Hoth Therapeutics, Inc.f10q0620ex31-1_hoththerap.htm
EX-10.8 - NOVATION AGREEMENT BY AND AMONG THE COMPANY, CHELEXA BIOSCIENCES, INC. AND THE U - Hoth Therapeutics, Inc.f10q0620ex10-8_hoththerap.htm
EX-10.7 - ROYALTY AGREEMENT BY AND BETWEEN THE COMPANY AND CHELEXA BIOSCIENCES, INC. DATED - Hoth Therapeutics, Inc.f10q0620ex10-7_hoththerap.htm
EX-10.6 - ASSIGNMENT AND ASSUMPTION AGREEMENT BY AND BETWEEN THE COMPANY AND CHELEXA BIOSC - Hoth Therapeutics, Inc.f10q0620ex10-6_hoththerap.htm
EX-10.5 - SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN THE UNIVERSITY OF - Hoth Therapeutics, Inc.f10q0620ex10-5_hoththerap.htm
EX-10.4 - FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN THE UNIVERSITY OF - Hoth Therapeutics, Inc.f10q0620ex10-4_hoththerap.htm
EX-10.3 - LICENSE AGREEMENT BY AND BETWEEN THE UNIVERSITY OF CINCINNATI AND CHELEXA BIOSCI - Hoth Therapeutics, Inc.f10q0620ex10-3_hoththerap.htm
10-Q - QUARTERLY REPORT - Hoth Therapeutics, Inc.f10q0620_hoththerapeutics.htm

Exhibit 32.1

 

Statement of Chief Executive Officer
Pursuant to Section 1350 of Title 18 of the United States Code

 

Pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Robb Knie, Chief Executive Officer of Hoth Therapeutics, Inc. (the “Company”), hereby certifies that based on the undersigned’s knowledge:

 

  1. The Company’s quarterly report on Form 10-Q for the period ended June 30, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 13, 2020 /s/ Robb Knie
  Robb Knie,
  Chief Executive Officer
(Principal Executive Officer)

  

Hoth Therapeutics, Inc. Reports